糖原合酶激酶3：阿尔茨海默病的整合点及治疗靶点？
Glycogen synthase kinase 3: a point of integration in Alzheimer's disease and a therapeutic target?
作者信息
Mondragón-Rodríguez Siddhartha, Perry George, Zhu Xiongwei, Moreira Paula I, Williams Sylvain
机构信息
Department of Psychiatry, Douglas Hospital Research Center, McGill University, Montreal, QC, Canada H4H 1R3.
出版信息
Int J Alzheimers Dis. 2012;2012:276803. doi: 10.1155/2012/276803. Epub 2012 Jun 14.
Abstract
Glycogen synthase kinase 3 (GSK3) has been implicated in neurological disorders; therefore, it is not surprising that there has been an increased focus towards developing therapies directed to this kinase. Unfortunately, these current therapies have not taken into consideration the physiological role of GSK3 in crucial events like synaptic plasticity. With this in mind we will discuss the relationship of synaptic plasticity with GSK3 and tau protein and their role as potential targets for the development of therapeutic strategies. Finally, we will provide perspectives in developing a cocktail therapy for Alzheimer's treatment.
摘要
糖原合酶激酶3（GSK3）与神经疾病有关；因此，越来越关注针对该激酶开发治疗方法也就不足为奇了。不幸的是，目前这些治疗方法并未考虑GSK3在诸如突触可塑性等关键事件中的生理作用。考虑到这一点，我们将讨论突触可塑性与GSK3和tau蛋白的关系，以及它们作为治疗策略开发潜在靶点的作用。最后，我们将为开发治疗阿尔茨海默病的联合疗法提供观点。
相似文献
1
Glycogen synthase kinase 3: a point of integration in Alzheimer's disease and a therapeutic target?
Int J Alzheimers Dis. 2012;2012:276803. doi: 10.1155/2012/276803. Epub 2012 Jun 14.
2
Amyloid Beta and tau proteins as therapeutic targets for Alzheimer's disease treatment: rethinking the current strategy.
Int J Alzheimers Dis. 2012;2012:630182. doi: 10.1155/2012/630182. Epub 2012 Mar 8.
3
Glycogen synthase kinase 3: more than a namesake.
Br J Pharmacol. 2009 Mar;156(6):885-98. doi: 10.1111/j.1476-5381.2008.00085.x. Epub 2009 Mar 4.
4
Glycogen synthase kinase 3: a drug target for CNS therapies.
J Neurochem. 2004 Jun;89(6):1313-7. doi: 10.1111/j.1471-4159.2004.02422.x.
5
Glycogen Synthase Kinase 3 (GSK3): Its Role and Inhibitors.
Curr Top Med Chem. 2020;20(17):1522-1534. doi: 10.2174/1568026620666200516153136.
6
Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging.
Expert Opin Ther Targets. 2018 Oct;22(10):833-848. doi: 10.1080/14728222.2018.1526925. Epub 2018 Sep 26.
7
The GSK3 hypothesis of Alzheimer's disease.
J Neurochem. 2008 Mar;104(6):1433-9. doi: 10.1111/j.1471-4159.2007.05194.x. Epub 2007 Dec 18.
8
AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans.
J Neurochem. 2013 May;125(3):446-56. doi: 10.1111/jnc.12203. Epub 2013 Mar 11.
9
Regulation of cell survival mechanisms in Alzheimer's disease by glycogen synthase kinase-3.
Int J Alzheimers Dis. 2011;2011:861072. doi: 10.4061/2011/861072. Epub 2011 May 11.
10
The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase.
Biochem J. 2001 May 1;355(Pt 3):609-15. doi: 10.1042/bj3550609.
引用本文的文献
1
An evidence-based approach to identify aging-related genes in Caenorhabditis elegans.
BMC Bioinformatics. 2015 Feb 7;16(1):40. doi: 10.1186/s12859-015-0469-4.
2
Amyloid beta-peptide worsens cognitive impairment following cerebral ischemia-reperfusion injury.
Neural Regen Res. 2013 Sep 15;8(26):2449-57. doi: 10.3969/j.issn.1673-5374.2013.26.006.
3
Amelioration of diabetes-induced cognitive deficits by GSK-3β inhibition is attributed to modulation of neurotransmitters and neuroinflammation.
Mol Neurobiol. 2014 Oct;50(2):390-405. doi: 10.1007/s12035-014-8632-x. Epub 2014 Jan 14.
4
Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease.
Free Radic Biol Med. 2014 Feb;67:387-95. doi: 10.1016/j.freeradbiomed.2013.11.014. Epub 2013 Dec 16.
5
Nebula/DSCR1 upregulation delays neurodegeneration and protects against APP-induced axonal transport defects by restoring calcineurin and GSK-3β signaling.
PLoS Genet. 2013;9(9):e1003792. doi: 10.1371/journal.pgen.1003792. Epub 2013 Sep 26.
6
Phosphorylation of tau protein as the link between oxidative stress, mitochondrial dysfunction, and connectivity failure: implications for Alzheimer's disease.
Oxid Med Cell Longev. 2013;2013:940603. doi: 10.1155/2013/940603. Epub 2013 Jul 10.
本文引用的文献
1
Inhibition of GSK3 by Wnt signalling--two contrasting models.
J Cell Sci. 2011 Nov 1;124(Pt 21):3537-44. doi: 10.1242/jcs.091991.
2
The cell biology of synaptic plasticity.
Science. 2011 Nov 4;334(6056):623-8. doi: 10.1126/science.1209236.
3
Pharmacological treatment of Alzheimer disease.
Can J Psychiatry. 2011 Oct;56(10):579-88. doi: 10.1177/070674371105601003.
4
Drugs: a tangled web of targets.
Nature. 2011 Jul 13;475(7355):S9-11. doi: 10.1038/475S9a.
5
Neuroprotective action of lithium in disorders of the central nervous system.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011 Jun;36(6):461-76. doi: 10.3969/j.issn.1672-7347.2011.06.001.
6
Mechanisms of tau self-aggregation and neurotoxicity.
Curr Alzheimer Res. 2011 Sep;8(6):608-14. doi: 10.2174/156720511796717258.
7
Association analysis of GSK3B and MAPT polymorphisms with Alzheimer's disease in Han Chinese.
Brain Res. 2011 May 19;1391:147-53. doi: 10.1016/j.brainres.2011.03.052. Epub 2011 Mar 26.
8
Raf kinase inhibitor protein RKIP enhances signaling by glycogen synthase kinase-3β.
Cancer Res. 2011 Feb 15;71(4):1334-43. doi: 10.1158/0008-5472.CAN-10-3102. Epub 2011 Feb 8.
9
Wnt signaling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes.
Cell. 2010 Dec 23;143(7):1136-48. doi: 10.1016/j.cell.2010.11.034.
10
LTP in hippocampal neurons is associated with a CaMKII-mediated increase in GluA1 surface expression.
J Neurochem. 2011 Feb;116(4):530-43. doi: 10.1111/j.1471-4159.2010.07133.x. Epub 2011 Jan 19.
Zotero 插件